Kovitz Investment Group Partners
ELDN icon

Kovitz Investment Group Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Kovitz Investment Group Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-732,975
Closed -$1.9M – 696
2025
Q3 		$1.9M Buy
+732,975
New +$2.14M 0.01% 679

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Kovitz Investment Group Partners's ELDN Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 732,975 shares — an estimated $1.9M sold.

Kovitz Investment Group Partners first reported a position in ELDN in Q3 2025 and held it in 1 quarter. The position peaked at $1.9M in Q3 2025. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 732,975 Eledon Pharmaceuticals shares in Q4 2025, an estimated $1.9M.
  • Kovitz Investment Group Partners first reported a position in Eledon Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Kovitz Investment Group Partners's Eledon Pharmaceuticals position peaked at $1.9M in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.